Batu Recruits Internationally Recognized Immunologist

Internationally-Recognized Immunologist Joins Batu Biologics’ Quest to Destroy Solid Tumors

Francesco Marincola, MD, Joins Batu’s Scientific Advisory Board

Batu Biologics, an immuno-oncology company dedicated to the development of its tumor endothelium vaccine, ValloVax™, announced today the appointment of Francesco M. Marincola, MD, FACS, to its scientific advisory board.

Read the full article at businesswire.com

Batu Seeks New Approach to Inhibit Immune Checkpoints

Batu Biologics Utilizes CRISPR/cas9 Gene Editing to Modify T Cells

Immune Checkpoint Silenced T Cells for More Potent, Longer Lasting Anti-Tumor Responses

Batu Biologics, an immuno-oncology company, has recently filed intellectual property and initiated discovery research on a new method of augmenting an anti-tumor immune response through ex vivo manipulation of the patient’s T cells.

Read the full article at businesswire.com

ValloVax Efficacy Augmented by Checkpoint Inhibitors

Batu Biologics Reports Combination Therapy Boosts Results in Tumor Blood Vessel-Killing Strategy

Company Files Patent on Second Generation Cancer Therapy

Batu Biologics, an immuno-oncology company dedicated to the commercialization of its first-in-class tumor blood vessel targeting vaccine, ValloVax, reported today filing of a patent application covering a unique combination therapy of its vaccine together with two classes of “checkpoint inhibitors.”

Read the full article at businesswire.com

Batu Biologics files IP for immune modulator

Batu Biologics Files Patent on Blood Derived Anti-Cancer Immunomodulator

Cancer Angiogenesis Vaccine Company Expands its Therapeutic Pipeline

Batu Biologics announced today filing of a patent application covering a recent finding by the company regarding ability to stimulate innate immune system through products that are coaxed out of white blood cells by stimulation with non-toxic agents.

Read the full article at businesswire.com

Batu Biologics Publishes Preclinical Data for ValloVax™

Batu Biologics Publishes Preclinical Data for ValloVax™

Company authors peer-reviewed publication about lung cancer immune therapy targeting the tumor endothelium

Batu Biologics announced today publication in the Journal of Translational Medicine of the rationale and preclinical data for Batu’s flagship immunotherapeutic product, ValloVax™.

Read the full article at businesswire.com

Batu Biologics Appoints Dr. Santosh Kesari to SAB

Batu Biologics Appoints Dr. Santosh Kesari to Scientific Advisory Board

UC San Diego Moores Cancer Expert to evaluate the clinical potential of ValloVax for Glioblastoma

Batu Biologics, an immuno-oncology company based out of San Diego dedicated to the development of its polyvalent tumor endothelium vaccine, ValloVax, announced today the appointment of Santosh Kesari, MD, PhD, FANA to its scientific advisory board.

Read the full article at businesswire.com

Batu Biologics Appoints Alan Lewis to Chairman of the Board

Batu Biologics Appoints Biopharmaceutical Executive Dr. Alan Lewis as Chairman of the Board

World Class Industry Expert to Accelerate Development of Cancer Immunotherapeutic Platform after IND Filing for Lung Cancer Indication

Batu Biologics, a San Diego biotechnology company dedicated towards the development of its cancer angiogenesis-targeting immunotherapeutic product, ValloVax, announced today the appointment of Dr. Alan Lewis as Chairman of the Board of Directors.

Read the full article at businesswire.com

Startup applies to test cancer therapy

Batu Biologics, a year-old startup, has filed to begin a clinical trial of its cancer vaccine, which seeks to harness the immune system to stop growth of new blood vessels that feed tumors.

The San Diego startup said Thursday that its therapy, ValloVax™, will be tested in a Phase 1/2 trial against non-small cell lung cancer once the U.S. Food and Drug Administration approves the application.

ValloVax™ targets proteins found in blood vessels induced by cancer that are not present in ordinary blood vessels. In mouse models, the vaccine inhibited tumor formation in melanoma, breast and lung cancer.

UCSD brain cancer specialist Dr. Santosh Kesari said he’s asked Batu if he can take part in the clinical trial.

“The innovative thing about this technology is that you’re combining two powerful, validated technologies in one: angiogenesis inhibitors and immunotherapy,” Kesari said. “I think it has a lot of potential.”

Read the full article as posted by U-T San Diego here

Bringing Innovative Weapons To the Cancer Battlefront

What if we could engineer “killer cells” to wage war on tumors, and then program the little soldiers to seek a specific kill zone? What if glowing tumors could tell doctors which tissue material to remove during surgery?

These are just two of the recent breakthroughs in cancer research being undertaken by the hundreds of local bio- tech firms that are pumping money and resources into the oncology market — a market that’s booming with players, inno- vations and a demand that just won’t quit.

San Diego-based Batu Biologics Inc., is taking a more inventive approach. Batu’s new cancer vaccine, ValloVax™, is designed to target and kill blood vessels that feed tumor growth. In doing so, Batu expects white blood cells to invade the tumor site and encourage immune-based remission. Without being able to form new blood vessels, a tumor cannot grow bigger than 1 millimeter, said 22-year-old CEO Samuel Wagner.

Wagner said the company is set to file an investigational new drug application with the U.S. Food and Drug Admin- istration in the first quarter of 2015, and hopes to begin clinical trials after approval. Batu recently signed a license agreement with the Regents of the University of California granting Batu exclusive rights to develop and commercialize their HMGB-1 derived vaccine platform, a technology that can be used in conjunction with ValloVax™ to “supercharge” the potency of the immune response.

Download the full article as seen in the San Diego Business Journal here